Enrico Piccinini | Senior Vice President, EU & International, Rare Diseases
Chiesi Group
Enrico Piccinini has been Senior Vice President, EU & International, Rare Diseases, Chiesi Group, since November 2019, where he leads a team that works to make treatments available for rare and ultra-rare diseases. He is a member of various biotech, R&D and orphan drug groups and associations, where he plays an active role, including leading the Farmindustria National Working Group on Rare Diseases in Italy since 2022. Prior to his time at Chiesi, he held a long tenure at Genzyme and Sanofi Genzyme in various sub-regional and regional roles, both functional and business, leading his team through several launches and sustained business growth in orphan and other specialty care diseases.
Appearances:
Pre-Congress Workshops - Monday 27th October @ 14:00
Enabling Digitally-Enhanced Care for Rare Diseases in Europe
Lysosomal Storage Disorders (LSDs) present significant challenges, including delayed diagnoses, fragmented care pathways, and limited access to specialist care. Digital health technologies offer a transformative opportunity to address unmet needs by enabling earlier intervention, enhancing care coordination, and empowering patients and healthcare providers with innovative tools.
Utilizing interactive tools and featuring multi-stakeholder perspectives from patients to industry and policymakers, this discussion will explore the integration of digital health innovations ranging from AI to telemedicine, digital medical devices, and other connected care technologies into care pathways for rare diseases across Europe
Day 1 - Tuesday 28 October @ 11:30
Working Group 2: From Insight to Action: Leveraging Patient Experience Data Across the Rare Disease Lifecycle
Understanding patient experiences, preferences, and behaviours is critical to developing treatments that truly meet patient needs. Yet in rare diseases, capturing and applying these insights remains difficult due to small, diverse populations, delayed diagnoses, a lack of standardized methods, and limited regulatory guidance.
This panel will explore how both qualitative, and semi-quantitative patient data can inform more effective, patient-centred decisions across the product lifecycle in the rare disease space. Experts will address key barriers, such as data integration, resource constraints, and methodological gaps, and share practical strategies and real-world examples to overcome them.
Join the panel and gain a clear view of what meaningful patient experience data look like and how they can drive clinical development strategies, as well as pre-launch and market success
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events